Pfister et al. confirmed the unfavorable effects of anti-PD-1 treatment on NASH in experimental mice models, providing evidence of the tissue-damaging role of CD8+PD-1+ T lymphocytes [203]. Here, RPL17 is linked to metabolic dysfunction-associated steatohepatitis.